Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $120.80 USD
Change Today 0.00 / 0.00%
Volume 0.0
AKBLF On Other Exchanges
Symbol
Exchange
Copenhagen
Berlin
OTC US
As of 8:10 PM 08/10/15 All times are local (Market data is delayed by at least 15 minutes).

alk-abello a/s (AKBLF) Snapshot

Open
$120.80
Previous Close
$120.80
Day High
$120.80
Day Low
$120.80
52 Week High
08/6/15 - $121.20
52 Week Low
12/11/14 - $113.00
Market Cap
1.1B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
9.2M
EX-Date
03/13/15
P/E TM
--
Dividend
$4.69
Dividend Yield
0.58%
Current Stock Chart for ALK-ABELLO A/S (AKBLF)

Related News

No related news articles were found.

alk-abello a/s (AKBLF) Related Businessweek News

No Related Businessweek News Found

alk-abello a/s (AKBLF) Details

ALK-Abelló A/S, a pharmaceutical company, engages in the research and development, production, and sale of products for the diagnosis, prevention, and treatment of allergies worldwide. The company offers allergy immunotherapy products as injections, sublingual drops, and sublingual tablets for various allergies, including grass, ragweed, house dust mite, tree, cat, bee, and wasp. It also offers adrenaline auto-injectors for the treatment of severe allergic reactions. In addition, the company’s development programs include GRAZAX for grass allergic (ARC) and asthma prevention; GRASTEK for grass ARC; RAGWITEK for ragweed ARC; house dust mite (HDM) sublingual tablet-based allergy immunotherapy (SLIT)-tablets for HDM asthma and rhinitis; tree SLIT-tablet for tree ARC; and Japanese cedar SLIT-tablet for cedar tree ARC. It has strategic partnership agreements with Merck & Co., Inc. and Torii Pharmaceutical Co., Ltd. to develop, register, and commercialize SLIT-tablets in North America and Japan. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.

1,833 Employees
Last Reported Date: 08/18/15
Founded in 1923

alk-abello a/s (AKBLF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

alk-abello a/s (AKBLF) Key Developments

ALK-Abelló A/S Announces Earnings Results for the Second Quarter and First Half of 2015; Revises Earnings Guidance for the Year 2015

ALK-Abelló A/S announced earnings results for the second quarter and first half of 2015. For the quarter, the company continued to deliver underlying growth in its base business in line with that of the first quarter of 2015. Overall financial performance was impacted by lower milestone payments compared to last year: second quarter revenue, including partner income, amounted to DKK 565 million from DKK 615 a year ago. Second quarter revenue in the base business grew by 1% in local currencies to DKK 546 million from DKK 516 a year ago. Underlying growth was 4% when adjusted for last year's one-off upfront payment from ALK's collaboration partner for China. Second quarter partner income from SLIT-tablets was DKK 19 million against DKK 99 million, due to lower milestone payments. Second quarter EBITDA before special items was DKK 20 million against DKK 109 million a year ago. Excluding milestone payments and sales royalties, EBITDA before special items increased to DKK 19 million from DKK 10 million a year ago. For the first half period, the company’s first half total revenue was DKK 1,215 million against DKK 1,299 million a year ago and base business revenue growth was 3%. First half EBITDA before special items was DKK 158 million against DKK 320 million a year ago. Excluding sales royalties and milestone payments, EBITDA before special items grew to DKK 151 million against DKK 140 million a year ago, reflecting improved underlying profitability in the base business. For the year 2015, the full-year guidance has been adjusted to reflect the year-to-date sales growth in the base business and postponed investments: The company now expects to grow revenue in the base business by 3-5% in local currencies (previously 0-5%) based on low single-digit growth in Europe and high single-digit growth in non-European markets. Full-year revenue for the base business is expected to be DKK 2.3 billion to DKK 2.35 billion (previously DKK 2.25 billion to DKK 2.35 billion). The SLIT-tablet partnerships in North America and International markets are expected to generate additional revenue in the form of sales royalties, product supply, service fees and, potentially, milestone payments. Operating profit (EBITDA before special items), excluding sales royalties and milestone payments from partnerships, is expected to be in the range of DKK 250 million to DKK 300 million (previously DKK 225 million to DKK 300 million). Exchange rates are not expected to materially affect EBITDA. Free cash flow is projected to be negative in the range of DKK 50 million to DKK 150 million excluding sales royalties and milestone payments from partners (previously negative in the range of DKK 100 million to DKK 200 million). The company has strengthened its financial position through an increase of mortgage loans of net DKK 330 million.

ALK-Abelló A/S, H1 2015 Earnings Call, Aug 18, 2015

ALK-Abelló A/S, H1 2015 Earnings Call, Aug 18, 2015

Alk Abello A/S and Merck Announce Encouraging Results from Phase III Allergic Rhinitis Trial

Alk Abello A/S has announced encouraging results from its partner, Merck, or MSD's North-American Phase III clinical trial of ALK's investigational sublingual allergy immunotherapy tablet, or SLIT-tablet, for the treatment of house dust mite, or HDM, allergic rhinitis. The trial demonstrated a statistically significant improvement in the primary endpoint in favour of HDM SLIT-tablet compared with placebo. The primary endpoint of the trial was to demonstrate a reduction in the 'Total Combined Rhinitis Score' (TCRS) which is the sum of the average daily rhinitis symptom score and the average daily medication score. The trial also showed that the treatment was generally well tolerated. The trial, a randomised, multi-centre, placebo controlled, double-blind, comparative trial, was initiated by MSD in March 2014 to further investigate the safety and efficacy of the HDM SLIT-tablet in patients with HDM allergic rhinitis. It involved approximately 1,500 patients in the USA and Canada and is part of the world's large ever allergy immunotherapy development programme, which also includes trials in Europe and Japan. MSD has informed ALK that they now plan to discuss the data and the plans for a regulatory submission of a Biological License Application (BLA) for the HDM SLIT-tablet with the FDA. The HDM SLIT-tablet is currently undergoing regulatory reviews in Europe and Japan based on a combined clinical development programme involving more than 4,000 patients, including the completion of two positive Phase III clinical trials for the treatment of HDM allergic rhinitis and one positive Phase III trial for the treatment of HDM allergic asthma.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKBLF:US $120.80 USD 0.00

AKBLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKBLF.
View Industry Companies
 

Industry Analysis

AKBLF

Industry Average

Valuation AKBLF Industry Range
Price/Earnings 38.8x
Price/Sales 3.0x
Price/Book 2.8x
Price/Cash Flow 36.2x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALK-ABELLO A/S, please visit www.alk-abello.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.